What it's for (Indications)
- Tiotropium bromide is a long-acting anticholinergic bronchodilator indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
- This therapy aims to reduce the exacerbation rate in patients with COPD.
- Furthermore, tiotropium bromide is approved for the maintenance treatment of asthma in patients aged 6 years and older.
- It functions to improve lung function and reduce severe exacerbations in asthma patients.
- It is crucial to note that tiotropium bromide is not indicated for the relief of acute bronchospasm; rather, it is a maintenance therapy designed for ongoing control of respiratory symptoms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the maintenance treatment of COPD, the recommended dosage of tiotropium via HandiHaler is one 18 mcg capsule inhaled once daily, using the HandiHaler device. Alternatively, using the Respimat inhaler, the recommended dosage for COPD is 2.5 mcg (two inhalations of 1.25 mcg each) once daily. For the maintenance treatment of asthma, in patients aged 6 years and older, the recommended dosage is 2.5 mcg (two inhalations of 1.25 mcg each) once daily via the Respimat inhaler. It is imperative that tiotropium is administered consistently once daily and not used more frequently than prescribed. Patients should be instructed on the correct use of their specific inhalation device (HandiHaler or Respimat) to ensure optimal drug delivery and therapeutic effect, as improper technique can lead to reduced efficacy. |
Safety & Warnings
Common Side Effects
- Common adverse reactions reported with tiotropium bromide include dry mouth, upper respiratory tract infection, pharyngitis, sinusitis, headache, cough, dyspepsia, urinary tract infection, and constipation.
- These effects are generally mild to moderate and often transient.
- More serious, albeit less common, adverse effects can occur, such as paradoxical bronchospasm, which can be life-threatening and requires immediate discontinuation of the drug.
- Other serious reactions include immediate hypersensitivity reactions (e.
- g.
- , angioedema, urticaria, rash), precipitation or worsening of narrow-angle glaucoma (manifesting as blurred vision, eye pain, or halos around lights), and urinary retention, particularly in patients with pre-existing prostatic hyperplasia or bladder-neck obstruction.
- Patients should be advised to seek prompt medical attention if any severe or persistent side effects are experienced.
Serious Warnings
- Black Box Warning: Tiotropium bromide does not carry a formal FDA Black Box Warning. However, several serious warnings and precautions warrant significant attention from healthcare providers and patients. It is critical to understand that tiotropium is a maintenance bronchodilator and is not indicated for the rapid relief of acute bronchospasm. Patients experiencing acute symptoms should use a short-acting beta-agonist. Paradoxical bronchospasm, which can be life-threatening, has been reported with inhaled therapies, including tiotropium; if this occurs, treatment must be discontinued immediately. Immediate hypersensitivity reactions, such as angioedema and urticaria, may occur. Caution is advised in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction, as tiotropium can exacerbate these conditions, leading to blurred vision, eye pain, or urinary retention, respectively. Patients should be instructed to seek immediate medical attention if any of these serious adverse effects develop.
- Tiotropium bromide is intended solely for maintenance treatment and must not be used for the relief of acute symptoms of bronchospasm or for the treatment of acute exacerbations of COPD or asthma.
- Acute symptoms should be managed with a short-acting beta-agonist (SABA).
- As with other inhaled anticholinergic medications, tiotropium can precipitate narrow-angle glaucoma.
- Patients should be advised to report symptoms such as eye pain or discomfort, blurred vision, or halos around lights.
- Furthermore, urinary retention may occur, particularly in patients with pre-existing prostatic hyperplasia or bladder-neck obstruction; caution is advised in these populations.
- Immediate hypersensitivity reactions, including angioedema, may occur; discontinue therapy if such reactions develop.
- Use with caution in patients with severe milk protein allergy when using formulations containing lactose (e.
- g.
- , HandiHaler).
How it Works (Mechanism of Action)
Tiotropium bromide is a long-acting, competitive, and reversible antagonist of muscarinic cholinergic receptors, specifically exhibiting a kinetic selectivity for M1 and M3 receptors over M2 receptors. By binding to the M3 muscarinic receptors located on the smooth muscle of the bronchial airways, tiotropium inhibits the bronchoconstrictive effects of acetylcholine, a neurotransmitter released from parasympathetic nerves. This inhibition leads to relaxation of the bronchial smooth muscle, resulting in bronchodilation. The prolonged duration of its bronchodilatory action is primarily attributed to its slow dissociation from the M3 muscarinic receptors, allowing for once-daily dosing. Its local action in the lungs minimizes systemic anticholinergic side effects.